Intensifying Competition in GLP-1 Weight Loss Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- Market Competition Analysis: Novo Nordisk's GLP-1 weight-loss drug Wegovy launched a new pill form in 2026, achieving 1.3 million prescriptions in Q1, which quickly rose to 2 million, indicating strong market demand and potential for long-term growth opportunities for the company.
- Financial Performance Comparison: Over the past three years, Novo Nordisk's stock has fallen by 40%, while Eli Lilly's has risen by over 150%, reflecting Eli Lilly's competitive advantage in the GLP-1 market, particularly regarding drug efficacy.
- Patent and Pricing Pressure: Novo Nordisk faces challenges with patent expiration in India and has been forced to cut prices in the U.S. market, putting pressure on sales; however, management expects volume growth from the Wegovy pill to offset the impact of price declines.
- Investor Focus: With a dividend yield of 3.9% compared to Eli Lilly's 0.6%, Novo Nordisk presents an attractive opportunity for long-term investors, despite the intense competition in the industry, as early successes suggest the company still has potential for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 43.960
Low
42.00
Averages
54.67
High
70.00
Current: 43.960
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Oral Weight Loss Pill Approved in the UK
- Drug Approval: Novo Nordisk's oral GLP-1 therapy, Wegovy, has been approved in the UK, providing an alternative to injectable weight loss medications for obese or overweight adults, which is expected to significantly enhance market share.
- Clinical Trial Results: In the OASIS 4 phase 3 clinical trial, adults taking the 25 mg Wegovy pill experienced nearly a 14% weight loss over 64 weeks, compared to a mere ~2% decline in the placebo group, demonstrating substantial efficacy.
- Market Expansion Plans: This approval allows Novo Nordisk to launch the drug in its second market outside the U.S., with plans to introduce it in select markets in the second half of the year, further driving company growth.
- Industry Impact: The introduction of oral Wegovy is expected to alleviate sales decline pressures for Novo Nordisk and position the company more favorably in the weight loss medication market, enhancing its competitiveness in the global healthcare sector.
See More
Pfizer's New Drug Intensifies Competition in Weight Loss Market
- Pfizer's Drug Introduction: Pfizer's weight loss drug berobenatide, requiring only monthly injections, is set to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially putting market pressure on both companies.
- Clinical Trial Results: The latest phase 2b trial showed an average weight loss of 15.9%, and while Novo Nordisk and Eli Lilly's drugs may perform better under clinical management, the convenience of berobenatide could attract more patients.
- Market Outlook Analysis: Morgan Stanley projects the weight loss drug market will reach $150 billion by 2035, and Pfizer's entry may weaken the pricing power of Novo Nordisk and Eli Lilly, impacting their future revenues.
- Long-term Strategic Impact: Pfizer plans to launch multiple weight loss drugs in the coming years, and although the short-term revenue contribution may be limited, the enhanced competitiveness poses a potential threat to shareholders of Novo Nordisk and Eli Lilly.
See More
Pfizer Enters Weight Loss Drug Market with Berobenatide
- Drug Development Progress: Pfizer's weight loss drug berobenatide shows promise in its latest phase 2b trial, indicating potential for monthly injections with an average weight loss of 15.9% over 32 weeks, providing new hope for Pfizer in a competitive market.
- Increased Market Competition: With Pfizer entering the weight loss drug market, it will compete against giants like Novo Nordisk and Eli Lilly, which reported sales of $30 billion and $13.5 billion respectively, potentially undermining the pricing power of existing products.
- Diverse Clinical Trials: Pfizer is conducting multiple clinical trials for berobenatide, including 10 trials entering phase 3, indicating accelerated investment and strategic positioning in the weight loss drug sector.
- Long-Term Growth Potential: Pfizer anticipates a high single-digit revenue CAGR starting in 2029, although short-term performance may be impacted by declining COVID-19 drug sales, the potential of its weight loss drug business remains noteworthy.
See More
Novartis Unveils Phase 3 Data for Rhapsido in Chronic Inducible Urticaria
- Clinical Trial Results: Novartis presented late-breaking Phase 3 RemIND trial data at the EAACI Congress, demonstrating that Rhapsido met primary endpoints across the three most common subtypes of chronic inducible urticaria, showing potential as the first targeted therapy with responses observed as early as week 2 and sustained improvements by week 12.
- Market Need: Chronic inducible urticaria affects approximately 29 million people globally, and current antihistamine treatments often provide incomplete relief; Rhapsido, as a selective BTK inhibitor, addresses this significant unmet need by blocking histamine release, a key driver of hives and swelling.
- Efficacy Comparison: In the RemIND trial, complete response rates at week 12 were 29.3% for symptomatic dermographism, 56.3% for cold urticaria, and 29.3% for cholinergic urticaria, compared to only 14-16% for placebo, highlighting Rhapsido's significant efficacy.
- Future Plans: Novartis has submitted a supplemental NDA to the FDA for the symptomatic dermographism subtype and plans additional global filings in 2026; Rhapsido is already approved for chronic spontaneous urticaria in multiple regions, with potential to expand into the chronic inducible urticaria market.
See More
Viking Therapeutics Stock Potential Analysis
- Market Potential: Viking Therapeutics' stock has surged over 300% in the past five years, despite recent declines, indicating strong potential in the nearly $100 billion weight loss drug market, with significant revenue growth expected in the coming years.
- Clinical Trial Progress: The company anticipates reporting data from its maintenance dosing study in Q3 and plans to launch a phase 3 trial for the oral version in Q4, which could serve as catalysts for a stock rebound.
- Product Differentiation Advantage: Viking's VK2735 is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formats, and if approved, it would be the first drug to offer both formulations, catering to diverse patient needs.
- Market Reaction Potential: Viking's stock has shown sensitivity to news, previously soaring over 100% in a single day following phase 2 data release, suggesting that positive updates could propel the stock towards the $100 target.
See More
Viking Therapeutics Advances in Weight Loss Drug Development
- Massive Market Potential: Viking Therapeutics is developing candidates in the weight loss drug market, projected to reach nearly $100 billion in the coming years; although the company has yet to commercialize any drugs, its lead candidate VK2735 is in late-stage studies, indicating strong market prospects.
- Clinical Trial Progress: Viking plans to launch a phase 3 trial for the oral version of VK2735 in Q4 and expects to report data from a maintenance dosing study in Q3, with these catalysts potentially driving stock price recovery, especially after a decline over the past year.
- Product Differentiation Advantage: VK2735, as the first dual GLP-1/GIP receptor agonist available in both injectable and oral forms, can cater to varying patient needs during weight loss, potentially attracting more users and generating significant revenue for the company.
- Stock Price Recovery Expectations: Despite Viking's current stock price of about $27, Wall Street's average estimate suggests it could rise above $92 within the next 12 months, representing over 200% growth potential, reflecting optimistic market sentiment regarding its future performance.
See More
Novo Nordisk's Oral Weight Loss Pill Approved in the UK
- Drug Approval: Novo Nordisk's oral GLP-1 therapy, Wegovy, has been approved in the UK, providing an alternative to injectable weight loss medications for obese or overweight adults, which is expected to significantly enhance market share.
- Clinical Trial Results: In the OASIS 4 phase 3 clinical trial, adults taking the 25 mg Wegovy pill experienced nearly a 14% weight loss over 64 weeks, compared to a mere ~2% decline in the placebo group, demonstrating substantial efficacy.
- Market Expansion Plans: This approval allows Novo Nordisk to launch the drug in its second market outside the U.S., with plans to introduce it in select markets in the second half of the year, further driving company growth.
- Industry Impact: The introduction of oral Wegovy is expected to alleviate sales decline pressures for Novo Nordisk and position the company more favorably in the weight loss medication market, enhancing its competitiveness in the global healthcare sector.
See More
Pfizer's New Drug Intensifies Competition in Weight Loss Market
- Pfizer's Drug Introduction: Pfizer's weight loss drug berobenatide, requiring only monthly injections, is set to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially putting market pressure on both companies.
- Clinical Trial Results: The latest phase 2b trial showed an average weight loss of 15.9%, and while Novo Nordisk and Eli Lilly's drugs may perform better under clinical management, the convenience of berobenatide could attract more patients.
- Market Outlook Analysis: Morgan Stanley projects the weight loss drug market will reach $150 billion by 2035, and Pfizer's entry may weaken the pricing power of Novo Nordisk and Eli Lilly, impacting their future revenues.
- Long-term Strategic Impact: Pfizer plans to launch multiple weight loss drugs in the coming years, and although the short-term revenue contribution may be limited, the enhanced competitiveness poses a potential threat to shareholders of Novo Nordisk and Eli Lilly.
See More
Pfizer Enters Weight Loss Drug Market with Berobenatide
- Drug Development Progress: Pfizer's weight loss drug berobenatide shows promise in its latest phase 2b trial, indicating potential for monthly injections with an average weight loss of 15.9% over 32 weeks, providing new hope for Pfizer in a competitive market.
- Increased Market Competition: With Pfizer entering the weight loss drug market, it will compete against giants like Novo Nordisk and Eli Lilly, which reported sales of $30 billion and $13.5 billion respectively, potentially undermining the pricing power of existing products.
- Diverse Clinical Trials: Pfizer is conducting multiple clinical trials for berobenatide, including 10 trials entering phase 3, indicating accelerated investment and strategic positioning in the weight loss drug sector.
- Long-Term Growth Potential: Pfizer anticipates a high single-digit revenue CAGR starting in 2029, although short-term performance may be impacted by declining COVID-19 drug sales, the potential of its weight loss drug business remains noteworthy.
See More
Novartis Unveils Phase 3 Data for Rhapsido in Chronic Inducible Urticaria
- Clinical Trial Results: Novartis presented late-breaking Phase 3 RemIND trial data at the EAACI Congress, demonstrating that Rhapsido met primary endpoints across the three most common subtypes of chronic inducible urticaria, showing potential as the first targeted therapy with responses observed as early as week 2 and sustained improvements by week 12.
- Market Need: Chronic inducible urticaria affects approximately 29 million people globally, and current antihistamine treatments often provide incomplete relief; Rhapsido, as a selective BTK inhibitor, addresses this significant unmet need by blocking histamine release, a key driver of hives and swelling.
- Efficacy Comparison: In the RemIND trial, complete response rates at week 12 were 29.3% for symptomatic dermographism, 56.3% for cold urticaria, and 29.3% for cholinergic urticaria, compared to only 14-16% for placebo, highlighting Rhapsido's significant efficacy.
- Future Plans: Novartis has submitted a supplemental NDA to the FDA for the symptomatic dermographism subtype and plans additional global filings in 2026; Rhapsido is already approved for chronic spontaneous urticaria in multiple regions, with potential to expand into the chronic inducible urticaria market.
See More
Viking Therapeutics Stock Potential Analysis
- Market Potential: Viking Therapeutics' stock has surged over 300% in the past five years, despite recent declines, indicating strong potential in the nearly $100 billion weight loss drug market, with significant revenue growth expected in the coming years.
- Clinical Trial Progress: The company anticipates reporting data from its maintenance dosing study in Q3 and plans to launch a phase 3 trial for the oral version in Q4, which could serve as catalysts for a stock rebound.
- Product Differentiation Advantage: Viking's VK2735 is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formats, and if approved, it would be the first drug to offer both formulations, catering to diverse patient needs.
- Market Reaction Potential: Viking's stock has shown sensitivity to news, previously soaring over 100% in a single day following phase 2 data release, suggesting that positive updates could propel the stock towards the $100 target.
See More
Viking Therapeutics Advances in Weight Loss Drug Development
- Massive Market Potential: Viking Therapeutics is developing candidates in the weight loss drug market, projected to reach nearly $100 billion in the coming years; although the company has yet to commercialize any drugs, its lead candidate VK2735 is in late-stage studies, indicating strong market prospects.
- Clinical Trial Progress: Viking plans to launch a phase 3 trial for the oral version of VK2735 in Q4 and expects to report data from a maintenance dosing study in Q3, with these catalysts potentially driving stock price recovery, especially after a decline over the past year.
- Product Differentiation Advantage: VK2735, as the first dual GLP-1/GIP receptor agonist available in both injectable and oral forms, can cater to varying patient needs during weight loss, potentially attracting more users and generating significant revenue for the company.
- Stock Price Recovery Expectations: Despite Viking's current stock price of about $27, Wall Street's average estimate suggests it could rise above $92 within the next 12 months, representing over 200% growth potential, reflecting optimistic market sentiment regarding its future performance.
See More
